PROCEPT BioRobotics is a surgical robotics company enabling better patient care by developing transformative solutions in urology.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/30/2021 | Series G | $85MM | $xx.xx | $87.26B | Cpmg, Duquesne Family Office, Fidelity, Perceptive Advisors, T. Rowe Price Associates, Viking Global Investors Lp | |
Price per Share
$xx.xx
Shares Outstanding
21,125,900
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cpmg, Duquesne Family Office, Fidelity, Perceptive Advisors, T. Rowe Price Associates, Viking Global Investors Lp
|
||||||
07/30/2020 | Series F | $77.52MM | $xx.xx | $52.99B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
25,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
01/21/2018 | Series E | $121.15MM | $xx.xx | $39.76B | Cpmg, Perceptive Advisors, Viking Global Investors Lp | |
Price per Share
$xx.xx
Shares Outstanding
41,921,856
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cpmg, Perceptive Advisors, Viking Global Investors Lp
|
||||||
07/08/2015 | Series D | $41.91MM | $xx.xx | $9.36B | Cpmg, Novo A/S | |
Price per Share
$xx.xx
Shares Outstanding
39,165,154
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cpmg, Novo A/S
|
||||||
09/30/2013 | Series C | $7.14MM | $xx.xx | $4.24B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
7,433,046
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
01/29/2009 | Series A | $3.13MM | $xx.xx | $2.5B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,905,312
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
01/29/2009 | Series B | $5.96MM | $xx.xx | $2.5B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
8,748,576
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|